LCD-L37738
Document details
Summary
The introduction of MRgFUS for treating essential tremor and tremor dominant Parkinson's disease may lead to increased billing opportunities for facilities that provide this service. As reimbursementNew MRgFUS service could boost treatment billing opportunities.
Affected codes
ICD-10-CM
Affected specialty
Neurology alerts →Source document
https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37738&ver=23CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy FDA-BLA125360 · Neurology
Xeomin (incobotulinumtoxinA) is an injectable botulinum toxin type A administered via injection, placing it squarely in the Medicare Part B pathway for physician-administered drugs. It is reimbursed u
View alertPolicy FDA-BLA761149 · Neurology
Enspryng (Satralizumab) is an injectable drug approved for Part B billing, likely leading to a new J-code assignment. With its status as an orphan drug, it may qualify for pass-through payment under M
View alertPolicy FDA-BLA761063 · Neurology
Emgality (galcanezumab) is likely to receive a new J-code for billing under Medicare Part B since it is an injectable drug. The drug may be eligible for ASP+6% reimbursement, given its injectable stat
View alertPolicy FDA-BLA761119 · Neurology
VYEPTI (Eptinezumab-JJMR) is an injectable medication likely to receive a J-code for billing under Medicare Part B. Its category may allow for ASP+6% reimbursement, but billing teams should confirm th
View alert